Exousia Bio, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a LMMY research report →
Price Chart
About the company
Exousia Bio, Inc. is a biotechnology company that designs, develops, and manufactures mammalian- and plant-derived exosomes using proprietary technologies for nucleic acid loading and targeted delivery to tissues and cells. The company's platform enables the custom production of exosomes with enhanced genetic functionality that can selectively target specific cells to address diseases.
- CEO
- Matthew Dwyer
- IPO
- 2024
- Employees
- 2
- HQ
- Saint Petersburg, FL, US
Get TickerSpark's AI analysis on LMMY
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.26M
- P/E
- -9.23
- PEG
- 0.10
- P/S
- 0.00
- P/B
- 0.12
- EV/EBITDA
- -3.05
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -1.44%
- ROIC
- -2.34%
Latest fiscal year · YoY change
- Revenue
- $3.75K-67.4%
- Gross Profit
- $-3,501-291.0%
- Op Income
- $-31,881
- Net Income
- $51.40K+299.2%
- EPS
- $0.01+300.0%
- OCF Growth
- +0.0%
- FCF Growth
- +0.0%
- 52W High
- $0.94
- 52W Low
- $0.12
- 50D MA
- $0.39
- 200D MA
- $0.40
- Beta
- 0.00
- RSI (14)
- 31
- Avg Volume
- 133
No earnings-call transcripts are available for LMMY yet.
- Free Float
- 32.5%
- Shares Outstanding
- 7.78M
- Float Shares
- 2.53M
Our LMMY coverage
Recent articles, reports, and earnings notes.
No research on LMMY yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate LMMY report →Exousia Pro, Inc. Completes Exclusive Licensing Agreement With the University of Central Florida for Novel Cancer Diagnostic and Therapy Platforms
accessnewswire.com · Dec 2
LAMY Completes Strategic Acquisition of Cancer Therapy Innovator Exousia AI, Inc.
globenewswire.com · Dec 2
LAMY Completes Strategic Acquisition of Cancer Therapy Innovator Exousia AI, Inc.
globenewswire.com · Dec 2
Exousia Pro Initiates Strategic Realignment, Acquires Controlling Stake in SEC-Reporter Lamy (LMMY) in All-stock Exchange Transaction for Exousia AI, to Advance Growth and Enhance Shareholder Value
accessnewswire.com · Nov 17
LAMY Inc. Accelerates Strategic Upgrades, Deepens Global Presence and Technological Innovation
accessnewswire.com · Apr 25
LAMY Unveils GenZ Financial Literacy Initiative Powered by User-Generated Content and Creator Economy Tools
accessnewswire.com · Apr 22
LAMY Discusses The Smart Education Market Entering a Golden Era of Growth
accessnewswire.com · Mar 14
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.